ISI raised price target to $380, driven by renewed patent licensing agreements between Apple and Qualcomm, and strong iPhone 18 demand.
1 report, 1 independent
Updated Sep 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ISI raised price target to $380, driven by renewed patent licensing agreements between Apple and Qualcomm, and strong iPhone 18 demand.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- ISI
-
Apple Inc.
American multinational technology company based in Cupertino, California
-
Qualcomm
American global semiconductor company
Related events
- Intel's revenue forecast, Apple's iPhone launches, and PC slowdown are driving market shifts among chipmakers.
- ISI (Twist Bioscience) was listed on the Nasdaq stock exchange, and Barclays raised its price target on the company on July 9, 2026.
- iPhone revenue surged 22% to $54.3 billion, reflecting strong performance in the consumer device market.